Modified RNA with pseudouridine that extends in vivo gene therapy and silencing payloads without licensing constraints.
This technology builds RNA and gene-therapy vectors that incorporate pseudouridine (a modified nucleoside) to alter how the RNA behaves in cells. It’s technically significant because pseudouridine-modified RNA is engineered for stronger functional performance than unmodified RNA, enabling more effective gene replacement and transcription silencing from the same delivery format. Previously, using these specific modified-nucleoside RNA compositions and vectors required permission under the patent’s claims.
Launch pseudouridine-modified RNA therapeutics for gene replacement, CRISPR-like silencing, or in vivo protein delivery.
Submit a problem you're solving with this technology and connect with founders, investors, and researchers.